Citations

Clear

3030 citation(s) found for "Susan, M".

Evaluation of Siltuximab and Tocilizumab Analytical Interference on Interleukin 6 Measurements
Kian, Susan Ashrafzadeh, Deters, Rebecca, Irvine, Clayton , Bornhorst, Joshua A. , Bornhorst, Joshua , Wang, Qian , Algeciras‐Schimnich, Alicia

Mayo Clinic

American Journal of Clinical Pathology | November 29, 2023 | Volume: 160 | Issue: Supplement_1 | Pages: S123-S124

10.1093/ajcp/aqad150.269 Get It

Abstract Background Interleukin 6 (IL-6) plays important roles in both innate and adaptive immunity, while dysregulated persistent production of IL-6 is involved in pathological development of various diseases associated with inflammation. Targeting the IL-6 pathway has led to many innovative treatment approaches. Siltuximab and Tocilizumab are monoclonal antibodies targeting IL-6 and IL-6 receptors respectively and have been FDA-approved for treatment of Castleman disease (Siltuximab), a rare lymphoproliferative disorder characterized by hyperproduction of IL-6 with an unknown prevalence, autoimmune diseases such as rheumatoid arthritis (Tocilizumab), and both shown potential as treatment for cytokine release syndrome in hospitalized COVID-19 patients. However, the presence of siltuximab can interfere with IL-6 assays, leading to the use of C-reactive protein (CRP) as a surrogate marker to monitor its efficacy. Aim To evaluate potential Siltuximab and Tocilizumab antibody interference on IL-6 measurements in three different IL-6 protein immunoassays. Method: Serum or EDTA plasma sample pools with different IL-6 concentrations ranging from low (2.3 – 11.1 pg/mL, around the reference interval cut-off for each assay) to high (18.5 – 1142 pg/mL), above reference interval cut-off for each assay) were utilized. Various concentrations of Siltuximab or Tocilizumab were spiked into the sample pools (at 10% of total volume) to achieve final concentrations up to 600 µg/mL and up to 300 µg/mL, respectively. Sample spiked with 10% saline were used as no-drug control. Three assays were used to measure IL-6 concentration: Beckman Access IL-6 assay on UniCel DxI 800 (Beckman Coulter), V-PLEX Plus human IL-6 assay on QuickPlex SQ120 (Meso Scale Diagnostics), and a Luminex cytokine panel assay developed in house (R&D systems) with upper reference interval limits of 6.4,1.8 and 5 pg/mL respectively. Results Siltuximab interfered with the measurement of IL-6 for all three assays. A significant interference (> 20% reduction) was observed at even a very low siltuximab concentrations in all three assays (0.05 µg/mL). In the presence of 5 µg/mL or greater Siltuximab, a maximum reduction of 93%, 83%, and 40% was observed for Beckman Access, R&D Luminex assay, and V-PLEX Plus Mesoscale assay, respectively. Tocilizumab did not interfere with the measurement of IL-6 in the three assays when serum was spiked with up to 300 µg/mL of the drug. Conclusion Siltuximab falsely reduce the measured IL-6 concentration on all three immunoassays tested in this study to differing degrees, whereas Tocilizumab does not. Consider the therapeutic range of Siltuximab (84 to 332 µg/mL) for treatment of Castleman disease, and a half-life of 20.6 days, measurement of IL-6 may not be useful in Siltuximab treated patients for an extended time-period.
Physical Activity During Adolescence and Early-adulthood and Ovarian Cancer Among Women with a BRCA1 or BRCA2 Mutation
Guyonnet, Emma , Kim, Shana J. , Xia, Yue Yin , Giannakeas, Vasily , Armel, Susan Randall , Eisen, Andrea , Bordeleau, Louise , Eng, Charis , Olopade, Olufunmilayo I. , Narod, Steven A. , Lubinski, Jan , Randall Armel, Susan , Eisen, Andrea , Bordeleau, Louise , Eng, Charis , Olopade, Olufunmilayo I , Tung, Nadine , Foulkes, William D , Couch, Fergus J. , Aeilts, Amber M , Narod, Steven A , Kotsopoulos, Joanne , Lubiński, Jan , Tung, Nadine , Foulkes, William D. , Couch, Fergus J. , Aeilts, Amber M. , Kotsopoulos, Joanne

Mayo Clinic

Cancer Research Communications | November 28, 2023 | Volume: 3 | Issue: 11 | Pages: 2420-2429

10.1158/2767-9764.crc-23-0223 | PMID 38019076 Get It

Abstract In the general population, physical activity has been associated with a lower risk of several cancers; however, the evidence for ovarian cancer is not clear. It is suggested that early-life physical activity may differentially impact risk. Whether this is true among women at high risk due to a pathogenic variant (mutation) in the BRCA1 or BRCA2 genes has not been evaluated. Thus, we performed a matched case–control study to evaluate the association between adolescent and early-adulthood physical activity and ovarian cancer. BRCA mutation carriers who completed a research questionnaire on various exposures and incident disease and with data available on physical activity were eligible for inclusion. Self-reported activity at ages 12–13, 14–17, 18–22, 23–29, and 30–34 was used to calculate the average metabolic equivalent of task (MET)-hours/week for moderate, vigorous, and total physical activity during adolescence (ages 12–17) and early-adulthood (ages 18–34). Conditional logistic regression was used to estimate the OR and 95% confidence intervals (CI) of invasive ovarian cancer associated with physical activity. This study included 215 matched pairs (mean age = 57.3). There was no association between total physical activity during adolescence (ORhigh vs. low = 0.91; 95% CI: 0.61–1.36; Ptrend = 0.85), early-adulthood (ORhigh vs. low = 0.78; 95% CI: 0.51–1.20; Ptrend = 0.38) and overall (ORhigh vs. low = 0.81; 95% CI: 0.54–1.23; Ptrend = 0.56) and ovarian cancer. Findings were similar for moderate (Ptrend ≥ 0.25) and vigorous (Ptrend ≥ 0.57) activity. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, physical activity should continue to be encouraged to promote overall health. Significance: In this matched case–control study, we observed no association between physical activity during adolescence or early-adulthood and subsequent risk of ovarian cancer. These findings do not provide evidence for an association between early-life physical activity and BRCA-ovarian cancer; however, being active remains important to promote overall health and well-being.
Operationalizing selection criteria for clinical trials in Alzheimer's disease: Biomarker and clinical considerations
Petersen, Ronald C. , Graf, Ana, Brady, Chris, Santi, Susan De , Florian, Hana , Landen, Jaren W., Pontecorvo, Mike, Randolph, Christopher , Sink, Kaycee M. , Carrillo, María C. , Weber, Christopher J., Brady, Chris

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | November 17, 2023 | Volume: 9 | Issue: 4 | Pages: No page available

10.1002/trc2.12434 | PMID 38023620 Get It

Abstract Alzheimer's disease (AD) staging criteria lack standardized, empirical description. Well‐defined AD staging criteria are an important consideration in protocol design, influencing a more standardized inclusion/exclusion criteria and defining what constitutes meaningful differentiation among the stages. However, many trials are being designed on the basis of biomarker features and the two need to be coordinated. The Alzheimer's Association Research Roundtable (AARR) Spring 2021 meeting discussed the implementation of preclinical AD staging criteria, and provided recommendations for how they may best be incorporated into clinical trials research. Discussion also included what currently available tools for global clinical trials may best define populations in preclinical AD trials, and if are we able to differentiate preclinical from clinical stages of the disease. Well‐defined AD staging criteria are key to improving early detection, diagnostics, clinical trial enrollment, and identifying statistically significant clinical changes, and researchers discussed how emerging blood biomarkers may help with more efficient screening in preclinical stages.
Effects of cohort, genotype, variant, and maternal β-blocker treatment on foetal heart rate predictors of inherited long QT syndrome
Kaizer, Alexander , Winbo, Annika , Clur, Sally‐Ann B. , Etheridge, Susan P. , Ackerman, Michael J. , Horigome, Hitoshi , Herberg, Ulrike , Dagradi, Federica , Spazzolini, Carla , Killen, Stacy A. S. , Wacker‐Gussmann, Annette , Wilde, Arthur A.M. , Sinkovskaya, Elena, Abuhamad, Alfred, Torchio, Margherita , Ng, Chai‐Ann , Rydberg, Annika , Schwartz, Peter J. , Cuneo, Bettina F. , Kaizer, Alexander M , Schwartz, Peter J. , Clur, Sally-Ann B , Cuneo, Bettina , Dagradi, Federica , Spazzolini, Carla

Mayo Clinic

Europace | November 17, 2023 | Volume: 25 | Issue: 11 | Pages: No page available

10.1093/europace/euad319 | PMID 37975542 Get It

Abstract Aims In long QT syndrome (LQTS), primary prevention improves outcome; thus, early identification is key. The most common LQTS phenotype is a foetal heart rate (FHR) < 3rd percentile for gestational age (GA) but the effects of cohort, genotype, variant, and maternal β-blocker therapy on FHR are unknown. We assessed the influence of these factors on FHR in pregnancies with familial LQTS and developed a FHR/GA threshold for LQTS. Methods and results In an international cohort of pregnancies in which one parent had LQTS, LQTS genotype, familial variant, and maternal β-blocker effects on FHR were assessed. We developed a testing algorithm for LQTS using FHR and GA as continuous predictors. Data included 1966 FHRs at 7–42 weeks’ GA from 267 pregnancies/164 LQTS families [220 LQTS type 1 (LQT1), 35 LQTS type 2 (LQT2), and 12 LQTS type 3 (LQT3)]. The FHRs were significantly lower in LQT1 and LQT2 but not LQT3 or LQTS negative. The LQT1 variants with non-nonsense and severe function loss (current density or β-adrenergic response) had lower FHR. Maternal β-blockers potentiated bradycardia in LQT1 and LQT2 but did not affect FHR in LQTS negative. A FHR/GA threshold predicted LQT1 and LQT2 with 74.9% accuracy, 71% sensitivity, and 81% specificity. Conclusion Genotype, LQT1 variant, and maternal β-blocker therapy affect FHR. A predictive threshold of FHR/GA significantly improves the accuracy, sensitivity, and specificity for LQT1 and LQT2, above the infant’s a priori 50% probability. We speculate this model may be useful in screening for LQTS in perinatal subjects without a known LQTS family history.
Preclinical Characterization of AZD9574, a Blood–Brain Barrier Penetrant Inhibitor of PARP1
Staniszewska, Anna D. , Pilger, Domenic , Gill, Sonja J. , Jamal, Kunzah , Bohin, Natacha , Guzzetti, Sofia , Gordon, Jacob , Hamm, Gregory , Mundin, Gill , Illuzzi, Giuditta , Rose, Jonathan , Hawthorne, Glen , González, Miguel A. Cortés , Halldin, Christer , Johnström, Peter , Schou, Magnus , Johannes, Jeffrey W. , Davies, B. R. , Cosulich, Sabina , O’Connor, Mark J. , Pike, Andy , McWilliams, Lisa , Maglennon, Gareth , Rose, Jonathan , Hawthorne, Glen , Cortes Gonzalez, Miguel , Halldin, Christer , Johnström, Peter , Schou, Magnus , Critchlow, Susan E , Fawell, Stephen , Johannes, Jeffrey W , Leo, Elisabetta , Davies, Barry R , Cosulich, Sabina , Sarkaria, Jann N , O'Connor, Mark J , Hamerlik, Petra , Sarkaria, Jann N. , Hamerlik, Petra

Mayo Clinic

Clinical Cancer Research | November 15, 2023 | Volume: 30 | Issue: 7 | Pages: 1338-1351

10.1158/1078-0432.ccr-23-2094 | PMID 37967136 Get It

Abstract Purpose: We evaluated the properties and activity of AZD9574, a blood–brain barrier (BBB) penetrant selective inhibitor of PARP1, and assessed its efficacy and safety alone and in combination with temozolomide (TMZ) in preclinical models. Experimental Design: AZD9574 was interrogated in vitro for selectivity, PARylation inhibition, PARP-DNA trapping, the ability to cross the BBB, and the potential to inhibit cancer cell proliferation. In vivo efficacy was determined using subcutaneous as well as intracranial mouse xenograft models. Mouse, rat, and monkey were used to assess AZD9574 BBB penetration and rat models were used to evaluate potential hematotoxicity for AZD9574 monotherapy and the TMZ combination. Results: AZD9574 demonstrated PARP1-selectivity in fluorescence anisotropy, PARylation, and PARP-DNA trapping assays and in vivo experiments demonstrated BBB penetration. AZD9574 showed potent single agent efficacy in preclinical models with homologous recombination repair deficiency in vitro and in vivo. In an O6-methylguanine-DNA methyltransferase (MGMT)–methylated orthotopic glioma model, AZD9574 in combination with TMZ was superior in extending the survival of tumor-bearing mice compared with TMZ alone. Conclusions: The combination of three key features—PARP1 selectivity, PARP1 trapping profile, and high central nervous system penetration in a single molecule—supports the development of AZD9574 as the best-in-class PARP inhibitor for the treatment of primary and secondary brain tumors. As documented by in vitro and in vivo studies, AZD9574 shows robust anticancer efficacy as a single agent as well as in combination with TMZ. AZD9574 is currently in a phase I trial (NCT05417594). See related commentary by Lynce and Lin, p. 1217
Calorie restriction reduces biomarkers of cellular senescence in humans
Aversa, Zaira, White, Thomas A. , Heeren, Amanda A., Hulshizer, Cassondra A., Zhang, Xu , Molina, Anthony , Redman, Leanne M. , Racette, Susan B. , Huffman, Kim M. , Bhapkar, Manjushri, Fielding, Roger A. , Atkinson, Elizabeth J. , Saul, Dominik , Zhang, Xu , Molina, Anthony J A , Khosla, Sundeep , Das, Sai Krupa , LeBrasseur, Nathan K , Redman, Leanne , Racette, Susan B , Martin, Corby K. , Khosla, Sundeep , LeBrasseur, Nathan K.

Mayo Clinic

Aging Cell | November 14, 2023 | Volume: 23 | Issue: 2 | Pages: No page available

10.1111/acel.14038 | PMID 37961856 Get It

Abstract Calorie restriction (CR) with adequate nutrient intake is a potential geroprotective intervention. To advance this concept in humans, we tested the hypothesis that moderate CR in healthy young‐to‐middle‐aged individuals would reduce circulating biomarkers of cellular senescence, a fundamental mechanism of aging and aging‐related conditions. Using plasma specimens from the Comprehensive Assessment of Long‐term Effects of Reducing Intake of Energy (CALERIE™) phase 2 study, we found that CR significantly reduced the concentrations of several senescence biomarkers at 12 and 24 months compared to an ad libitum diet. Using machine learning, changes in biomarker concentrations emerged as important predictors of the change in HOMA‐IR and insulin sensitivity index at 12 and 24 months, and the change in resting metabolic rate residual at 12 months. Finally, using adipose tissue RNA‐sequencing data from a subset of participants, we observed a significant reduction in a senescence‐focused gene set in response to CR at both 12 and 24 months compared to baseline. Our results advance the understanding of the effects of CR in humans and further support a link between cellular senescence and metabolic health.
CTNI-73. ALLIANCE A071601: PHASE II TRIAL OF BRAF/MEK INHIBITION IN NEWLY DIAGNOSED PAPILLARY CRANIOPHARYNGIOMAS
Twohy, Erin , Geyer, Susan, Gerstner, Elizabeth R. , Kabat, Brian, Thierauf, Julia , Ruff, Michael W. , Reardon, David A. , Cohen, Adam L. , Fuente, Macarena de la, Lesser, Glenn J. , Campian, Jian , Agarwalla, Pankaj K., Kumthekar, Priya , Mann, Bhupinder, Vora, Shivangi, Knopp, Michael, Iafrate, A. John , Brown, Paul D. , Barker, Frederick G., Brastianos, Priscilla K. , Kaufmann, Timothy J. , Tabrizi, Shervin , Bota, Daniela A. , Knopp, Michael V. , Curry, William T. , Cahill, Daniel P. , Shih, Helen A. , Santagata, Sandro , Galanis, Evanthia

Mayo Clinic

Neuro-Oncology | November 11, 2023 | Volume: 25 | Issue: Supplement_5 | Pages: v94-v94

10.1093/neuonc/noad179.0355 Get It

Abstract BACKGROUND Craniopharyngiomas, primary brain tumors of the pituitary-hypothalamic axis, can cause significant clinical sequelae. Treatment using surgery, radiation, or both often entails significant morbidity. In prior work, we demonstrated that ninety-five percent of papillary craniopharyngiomas (PCP) harbor BRAF V600E mutations (Brastianos et al. Nature Genetics 2014). In this multicenter National Cancer Institute cooperative group trial (Alliance A071601), we evaluated the safety and efficacy of BRAF/MEK inhibition in patients with PCP without prior irradiation. METHODS Eligible patients, with measurable disease and whose PCP screened positively for BRAF mutations, without prior radiation, received the BRAF/MEK inhibitor combination vemurafenib/cobimetinib in 28-day cycles. The primary endpoint of objective response rate at 4 months based on centrally determined volumetric data was evaluated in 16 patients on this single arm phase 2 trial. RESULTS Based on volumetric response criteria by central radiology review, 15 of 16 patients (94%; 95% CI: 70% to 100%) had a durable objective partial response to therapy. Thus, this study met primary endpoint for overall response rate. The median tumor reduction was 91% (range of 68% to 99%). Median follow-up was 22 months (95% CI: 19 to 30 months) and median number of treatment cycles was 8. Median progression-free survival and duration of response were not yet reached. Three patients progressed during follow-up after therapy was discontinued; none have died. The sole non-responder stopped treatment after eight days due to toxicity. Grade 3 toxicities at least possibly related to treatment occurred in 12 patients (rash in 6 patients). Grade 4 toxicities were observed in two patients: hyperglycemia (n=1) and increased creatine phosphokinase (n=1). Three patients discontinued treatment for adverse events. CONCLUSIONS Our study indicates that BRAF/MEK inhibitors are a safe and effective treatment for PCP without prior irradiation. Support: U10CA180821, U10CA180882; U24CA196171, U10CA180868 (NRG); Genentech; . ClinicalTrials.gov Identifier: NCT03224767.
NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023
Advani, Ranjana H. , Andreadis, B., Chang, Julie , Christian, Beth , deVos, Sven, Fayad, Luis , Hamid, Muhammad Saad , Hernandez‐Ilizaliturri, Francisco J. , Kaminski, Mark , Karimi, Yasmin , King, Rebecca L. , Krivacic, Susan, LaCasce, Ann S. , Messmer, Marcus , Narkhede, Mayur , Rabinovitch, Rachel , Roberts, Kenneth B. , Smith, Stephen D. , Svoboda, Jakub , Swinnen, Lode J., Tuscano, Joseph M. , Dwyer, Mary A., Sundar, Hema, Advani, Ranjana H , Karimi, Yasmin H , Zelenetz, Andrew D. , Gordon, Leo I. , Abramson, Jeremy S. , Bartlett, Nancy L. , Budde, Lihua E. , Caimi, Paolo F. , Dholaria, Bhagirathbhai , Habermann, Thomas M. , Hu, Boyu , Kelsey, Chris R. , Lim, Megan S. , Ramakrishnan, Praveen , Reid, Erin G , Saeed, Hayder , Vose, Julie M.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | November 7, 2023 | Volume: 21 | Issue: 11 | Pages: 1118-1131

10.6004/jnccn.2023.0057 | PMID 37935098 Get It

Novel targeted therapies (small molecule inhibitors, antibody–drug conjugates, and CD19-directed therapies) have changed the treatment landscape of relapsed/refractory B-cell lymphomas. Bruton’s tyrosine kinase (BTK) inhibitors continue to evolve in the management of mantle cell lymphoma (MCL), in both the relapsed/refractory and the frontline setting. Anti-CD19 CAR T-cell therapies are now effective and approved treatment options for relapsed/refractory follicular lymphoma (FL), diffuse large B-cell lymphoma (DLBCL), and MCL. Bispecific T-cell engagers represent a novel immunotherapeutic approach for relapsed FL and DLBCL after multiple lines of therapies, including prior CAR T-cell therapy. These NCCN Guideline Insights highlight the significant updates to the NCCN Guidelines for B-Cell Lymphomas for the treatment of FL, DLBCL, and MCL.
Patient Awareness of Heart Failure Diagnosis: A Community Study
Shropshire, Stacie J. , Fabbri, Matteo, Manemann, Sheila M., Roger, Véronique L. , Killian, Jill M. , Weston, Susan A., Chamberlain, Alanna M. , Chamberlain, Alanna M

Mayo Clinic

Journal of the American Heart Association | November 6, 2023 | Volume: 12 | Issue: 21 | Pages: No page available

10.1161/jaha.122.029284 | PMID 37929749 Get It

Background Heart failure (HF) is a complex disease that contributes to a high number of hospitalizations, deaths, and economic health care costs each year. However, among patients with HF, there is a lack of awareness of their HF diagnosis that has not been fully examined. Methods and Results Residents from 3 counties of southeast Minnesota with a first‐ever International Classification of Diseases, Ninth Revision ( ICD‐9 ) code 428 or Tenth Revision ( ICD‐10 ) code I50 between January 1, 2013 and March 31, 2016 (N=2461) were prospectively surveyed to measure HF self‐awareness. A total of 1114 patients returned the survey (response rate, 45%), and 787 had validated HF upon medical record review. Among these 787 patients with HF (mean age, 76 years; 53% men), 37% (n=293) were aware of their HF diagnosis. After adjustment, being a woman (odds ratio [OR], 1.56 [95% CI, 1.10–2.22]), having HF with reduced ejection fraction (OR, 1.58 [95% CI, 1.13–2.22]), attending the HF clinic (OR, 4.07 [95% CI, 2.25–7.36]), and having coronary artery disease (OR, 1.65 [95% CI, 1.16–2.37]) were all associated with increased awareness of an HF diagnosis. Conversely, having diabetes was associated with decreased awareness of an HF diagnosis (adjusted OR, 0.69 [95% CI, 0.50–0.95]). Conclusions Awareness of an HF diagnosis is low in a community population of patients with HF. Strategies to improve patient awareness of their diagnosis should be implemented to improve self‐care behaviors and outcomes in patients with HF.
Abstract 15627: Accumulation of Chronic Conditions in Patients
Manemann, Sheila M., Weston, Susan A., Killian, Jill M. , Ryu, Euijung , Roger, Véronique L. , Siontis, Konstantinos C. , Chamberlain, Alanna M. , Alonso, Álvaro , Noseworthy, Peter A. , Gersh, Bernard J.

Mayo Clinic

Circulation | November 6, 2023 | Volume: 148 | Issue: Suppl_1 | Pages: No page available

10.1161/circ.148.suppl_1.15627 Get It

Background: Multimorbidity is common in atrial fibrillation (AF), particularly among older patients who generally have multiple cardiovascular and non-cardiovascular chronic conditions. However, less is known about the accumulation of chronic conditions in younger patients with AF. Methods: Patients aged <65 with incident AF from 2013-2019 from a 27-county region in the Midwest (N=4907) were matched 1:1 on age (±5 years) and sex to referents from the same community. The index date for the matched pair was the date of first diagnosis of AF. Diagnosis of 20 other chronic conditions was ascertained from 3 years prior to index through 12/31/2022. Mean cumulative function curves were used to visualize the accumulation of conditions; Andersen-Gill models estimated associations between AF/referent status and accumulation of conditions. Results: The mean age was 55 years for both patients with AF and matched referents; 71% were male. In the 3 years leading up to AF diagnosis, only 4% of patients with AF had no additional chronic conditions and 69% had ≥3 chronic conditions. In contrast, 35% of referents had 0 and 32% had ≥3 chronic conditions. The accumulation of chronic conditions was accelerated in patients with AF compared to referents prior to AF diagnosis/index (Figure). After index, patients with AF had increased accumulation of chronic conditions (HR (95% CI): 1.93 (1.71-2.20), 1.82 (1.62-2.05), 1.68 (1.55-1.83), and 1.53 (1.44-1.64) for ages <50, 50-54, 55-59, and 60-64 years, respectively). After 1 year, the differences were attenuated in all age groups with no difference observed between patients with AF and referents in the oldest age group (1.26 (1.08-1.46), 1.28 (1.11-1.47), 1.13 (1.02-1.24), and 1.05 (0.97-1.13) for ages <50, 50-54, 55-59, and 60-64 years). Conclusion: Patients <65 years with AF have an increased accumulation of chronic conditions compared to those without AF, in particular prior to their AF diagnosis and within the first year after AF diagnosis.